Compare Heron Therapeutics Inc (HRTX) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Wendys Co — how do they compare? Heron Therapeutics Inc trades at $0.48 (market cap $91.46M), while Wendys Co trades at $7.78 (market cap $1.50B). The key difference: Wendys Co is far larger — about 16.4× Heron Therapeutics Inc's market cap, and Wendys Co pays a 7.13% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | WEN | |
|---|---|---|
Market Cap | $91.46M | $1.50B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.96 | $11.33 |
52-Week Low | $0.39 | $6.17 |
Enterprise Value | $189.36M | $5.31B |
Dividend Yield | — | 7.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Wendy's (WEN) trades at $7.805, up 0.58% with a bullish technical signal and recent earnings beats. The stock shows attractive valuation metrics with P/E of 10.07 and P/S of 0.68, though net margins have declined to 6.77%. Recent news highlights Project Fresh initiatives and China expansion plans, while the company maintains a $0.14 dividend payment scheduled for June 2026.
WEN presents a mixed outlook with strong valuation appeal and dividend yield offset by margin pressures and declining earnings. The stock's 28% monthly gain reflects retail investor enthusiasm, but fundamental challenges require careful monitoring of turnaround execution and competitive positioning in the crowded fast-food sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
